{"id":334559,"date":"2019-02-25T13:14:02","date_gmt":"2019-02-25T13:14:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=334559"},"modified":"2019-02-25T13:14:02","modified_gmt":"2019-02-25T13:14:02","slug":"biosimilar-monoclonal-antibodies-market-2019-global-analysis-opportunities-industry-applications-key-developments-and-forecast-to-2025","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/biosimilar-monoclonal-antibodies-market-2019-global-analysis-opportunities-industry-applications-key-developments-and-forecast-to-2025_334559.html","title":{"rendered":"Biosimilar Monoclonal Antibodies Market 2019 Global Analysis, Opportunities, Industry Applications, Key Developments And Forecast To 2025"},"content":{"rendered":"
Market Analysis Research Report On \u201cGlobal Biosimilar Monoclonal Antibodies Market 2019 Industry Growth, Size, Trends, Share, Opportunities And Forecast To 2025 \u201d To Their Research Database.<\/div>\n

Global Biosimilar Monoclonal Antibodies Market<\/a> <\/strong><\/p>\n

The global Biosimilar Monoclonal Antibodies market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biosimilar Monoclonal Antibodies market based on company, product type, end user and key regions.<\/p>\n

Request a Sample Report @<\/strong> https:\/\/www.wiseguyreports.com\/sample-request\/3757663-global-biosimilar-monoclonal-antibodies-market-insights-forecast-to-2025<\/strong><\/a><\/p>\n

The following manufacturers<\/strong> are covered in this report, with sales, revenue, market share for each company: 
ProMab Biotechnologies 
Allergan plc 
Abbott 
BioXpress Therapeutics 
Bayer 
Bio Farma 
Merck 
Therapeutics 
Biocon 
Boehringer Ingelheim 
Celltrion Inc. 
Coherus BioSciences Inc. 
Zydus-Cadila 
Genor BioPharma 
Intas Pharmaceuticals 
Novartis 
Pfizer 
Reliance Life Sciences<\/p>\n

This report studies the global market size of Biosimilar Monoclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilar Monoclonal Antibodies in these regions. 
This research report categorizes the global Biosimilar Monoclonal Antibodies market by top players\/brands, region, type and end user. This report also studies the global Biosimilar Monoclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.<\/p>\n

 <\/p>\n

Market size by Product<\/strong> 
Infliximab 
Rituximab 
Abciximab 
Trastuzumab 
Adalimumab 
Bevacizumab 
Market size by End User<\/strong> 
Oncology 
Chronic and Autoimmune Diseases 
Growth Hormone Deficiency 
Infectious Diseases 
Others<\/p>\n

Market size by Region<\/strong> 
North America 
United States 
Canada 
Mexico 
Asia-Pacific 
China 
India 
Japan 
South Korea 
Australia 
Indonesia 
Singapore 
Malaysia 
Philippines 
Thailand 
Vietnam 
Europe 
Germany 
France 
UK 
Italy 
Spain 
Russia 
Central & South America 
Brazil 
Rest of Central & South America 
Middle East & Africa 
GCC Countries 
Turkey 
Egypt 
South Africa<\/p>\n

The study objectives of this report are:<\/strong> 
To study and analyze the global Biosimilar Monoclonal Antibodies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. 
To understand the structure of Biosimilar Monoclonal Antibodies market by identifying its various subsegments. 
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). 
Focuses on the key global Biosimilar Monoclonal Antibodies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. 
To project the value and sales volume of Biosimilar Monoclonal Antibodies submarkets, with respect to key regions. 
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.<\/p>\n

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilar Monoclonal Antibodies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.<\/p>\n

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.<\/p>\n

Table of Contents-Key Points Covered<\/strong><\/p>\n

1 Study Coverage 
1.1 Biosimilar Monoclonal Antibodies Product 
1.2 Market Segments 
1.3 Key Manufacturers Covered 
1.4 Market by Type 
1.4.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Product 
1.4.2 Infliximab 
1.4.3 Rituximab 
1.4.4 Abciximab 
1.4.5 Trastuzumab 
1.4.6 Adalimumab 
1.4.7 Bevacizumab 
1.5 Market by End User 
1.5.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by End User 
1.5.2 Oncology 
1.5.3 Chronic and Autoimmune Diseases 
1.5.4 Growth Hormone Deficiency 
1.5.5 Infectious Diseases 
1.5.6 Others 
1.6 Study Objectives 
1.7 Years Considered<\/p>\n

……….<\/p>\n

11 Company Profiles 
11.1 ProMab Biotechnologies 
11.1.1 ProMab Biotechnologies Company Details 
11.1.2 Company Business Overview 
11.1.3 ProMab Biotechnologies Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.1.4 ProMab Biotechnologies Biosimilar Monoclonal Antibodies Products Offered 
11.1.5 ProMab Biotechnologies Recent Development 
11.2 Allergan plc 
11.2.1 Allergan plc Company Details 
11.2.2 Company Business Overview 
11.2.3 Allergan plc Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.2.4 Allergan plc Biosimilar Monoclonal Antibodies Products Offered 
11.2.5 Allergan plc Recent Development 
11.3 Abbott 
11.3.1 Abbott Company Details 
11.3.2 Company Business Overview 
11.3.3 Abbott Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.3.4 Abbott Biosimilar Monoclonal Antibodies Products Offered 
11.3.5 Abbott Recent Development 
11.4 BioXpress Therapeutics 
11.4.1 BioXpress Therapeutics Company Details 
11.4.2 Company Business Overview 
11.4.3 BioXpress Therapeutics Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.4.4 BioXpress Therapeutics Biosimilar Monoclonal Antibodies Products Offered 
11.4.5 BioXpress Therapeutics Recent Development 
11.5 Bayer 
11.5.1 Bayer Company Details 
11.5.2 Company Business Overview 
11.5.3 Bayer Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.5.4 Bayer Biosimilar Monoclonal Antibodies Products Offered 
11.5.5 Bayer Recent Development 
11.6 Bio Farma 
11.6.1 Bio Farma Company Details 
11.6.2 Company Business Overview 
11.6.3 Bio Farma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.6.4 Bio Farma Biosimilar Monoclonal Antibodies Products Offered 
11.6.5 Bio Farma Recent Development 
11.7 Merck 
11.7.1 Merck Company Details 
11.7.2 Company Business Overview 
11.7.3 Merck Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.7.4 Merck Biosimilar Monoclonal Antibodies Products Offered 
11.7.5 Merck Recent Development 
11.8 Therapeutics 
11.8.1 Therapeutics Company Details 
11.8.2 Company Business Overview 
11.8.3 Therapeutics Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.8.4 Therapeutics Biosimilar Monoclonal Antibodies Products Offered 
11.8.5 Therapeutics Recent Development 
11.9 Biocon 
11.9.1 Biocon Company Details 
11.9.2 Company Business Overview 
11.9.3 Biocon Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.9.4 Biocon Biosimilar Monoclonal Antibodies Products Offered 
11.9.5 Biocon Recent Development 
11.10 Boehringer Ingelheim 
11.10.1 Boehringer Ingelheim Company Details 
11.10.2 Company Business Overview 
11.10.3 Boehringer Ingelheim Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019) 
11.10.4 Boehringer Ingelheim Biosimilar Monoclonal Antibodies Products Offered 
11.10.5 Boehringer Ingelheim Recent Development 
11.11 Celltrion Inc. 
11.12 Coherus BioSciences Inc. 
11.13 Zydus-Cadila 
11.14 Genor BioPharma 
11.15 Intas Pharmaceuticals 
11.16 Novartis 
11.17 Pfizer 
11.18 Reliance Life Sciences<\/p>\n

Continued….<\/p>\n

Enquiry For Buying Report@<\/strong> https:\/\/www.wiseguyreports.com\/enquiry\/3757663-global-biosimilar-monoclonal-antibodies-market-insights-forecast-to-2025<\/strong><\/a><\/p>\n

 <\/strong><\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Market Analysis Research Report On \u201cGlobal Biosimilar Monoclonal Antibodies Market 2019 Industry Growth, Size, Trends, Share, Opportunities And Forecast To 2025 \u201d To Their Research Database. Global Biosimilar Monoclonal Antibodies Market The global Biosimilar Monoclonal Antibodies market is valued at … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-334559","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/334559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=334559"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/334559\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=334559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=334559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=334559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}